Oct 24
ImmunoGen licenses tumor technology to Bayer HealthCare (Pharmaceutical Business Review)
ImmunoGen, a biotechnology company, has announced that Bayer HealthCare has licensed exclusive worldwide rights to use ImmunoGens tumor-activated prodrug technology to develop anticancer compounds to an undisclosed target found on solid tumors.